For Immediate Release: May 20 2015
Medpace Adds Geriatric Psychiatrist to Expanding Team of Physicians in Neuroscience Drug Development Dr. Thomas R. Thompson Joins Medpace as Senior Director, Medical Affairs
CINCINNATI, OH — (May 20, 2015) – Thomas R. Thompson, M.D. has joined Medpace as Senior Director, Medical Affairs. Dr. Thompson has over 12 years of director level Phase II-IV experience in Psychiatry and Neurology drug development.
Medpace, a global drug and medical device Clinical Research Organization (CRO), is unique in its physiciandriven approach to clinical research which gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Medpace medical doctors provide strategic direction for study design and planning, train operational staff, work with primary investigators, provide medical monitoring, and meet with regulatory agencies. Dr. Thompson joins a team of highly-experienced neuroscience physicians and will broaden Medpace’s ability to support neuroscience research with a specialized focus in the psychiatric and geriatric psychiatric patient populations.
About Thomas R. Thompson, M.D.
Dr. Thompson is Board Certified in Psychiatry and Geriatric Psychiatry with clinical development experience in numerous indications including Parkinson’s disease, bipolar disorder, stroke, epilepsy, depression, schizophrenia, anxiety disorders, and pain. He has co-authored book chapters on psychiatry and has been published in numerous peer reviewed journals. With prior leadership roles in the pharmaceutical industry, Dr. Thompson has a breadth of experience including medical affairs, global clinical development, regulatory submissions, medical governance, and medical monitoring. Dr. Thompson received his B.S. in biology from the University of Central Florida, his M.D from Temple University of School of Medicine, and his Psychiatry and Geriatric Psychiatry certificate from Emory University School of Medicine.
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic and specialty areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, gastrointestinal diseases, regenerative medicine, pediatrics, and rare disease/orphan indications. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and six regions – the US, Europe, Central and Eastern Europe, India, Asia Pacific, and Africa. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.